Myriad's stock smacked by Medicare reimbursement reduction error

Myriad Genetics' ($MYGN) stock dropped 9% on Sept. 30, driven down by investors reacting to what appeared to be a proposed 48% Medicare reimbursement cut for one of the company's signature cancer diagnostic tests. It turns out there was no reduction, as the number came from a clerical error. Myriad was quick to advertise what happened, a major analyst firm upgraded the stock and then the price rebounded, closing Tuesday at $25.31, up 7.7%. But the one-day investor mini-panic over Myriad's situation underscored the industry's vulnerabilities once insurance coverage becomes uncertain. Story

Suggested Articles

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.